ImmunoCellular Therapeutics Pink Sheet Forecast - Simple Moving Average
IMUCDelisted Stock | USD 0.47 0.00 0.00% |
The Simple Moving Average forecasted value of ImmunoCellular Therapeutics on the next trading day is expected to be 0.47 with a mean absolute deviation of 0.05 and the sum of the absolute errors of 2.88. ImmunoCellular Pink Sheet Forecast is based on your current time horizon. Investors can use this forecasting interface to forecast ImmunoCellular Therapeutics stock prices and determine the direction of ImmunoCellular Therapeutics's future trends based on various well-known forecasting models. We recommend always using this module together with an analysis of ImmunoCellular Therapeutics' historical fundamentals, such as revenue growth or operating cash flow patterns.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. ImmunoCellular |
Most investors in ImmunoCellular Therapeutics cannot accurately predict what will happen the next trading day because, historically, stock markets tend to be unpredictable and even illogical. Modeling turbulent structures requires applying different statistical methods, techniques, and algorithms to find hidden data structures or patterns within the ImmunoCellular Therapeutics' time series price data and predict how it will affect future prices. One of these methodologies is forecasting, which interprets ImmunoCellular Therapeutics' price structures and extracts relationships that further increase the generated results' accuracy.
A two period moving average forecast for ImmunoCellular Therapeutics is based on an daily price series in which the stock price on a given day is replaced by the mean of that price and the preceding price. This model is best suited to price patterns experiencing average volatility. ImmunoCellular Therapeutics Simple Moving Average Price Forecast For the 19th of April
Given 90 days horizon, the Simple Moving Average forecasted value of ImmunoCellular Therapeutics on the next trading day is expected to be 0.47 with a mean absolute deviation of 0.05, mean absolute percentage error of 0, and the sum of the absolute errors of 2.88.Please note that although there have been many attempts to predict ImmunoCellular Pink Sheet prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that ImmunoCellular Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
ImmunoCellular Therapeutics Pink Sheet Forecast Pattern
Backtest ImmunoCellular Therapeutics | ImmunoCellular Therapeutics Price Prediction | Buy or Sell Advice |
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Moving Average forecasting method's relative quality and the estimations of the prediction error of ImmunoCellular Therapeutics pink sheet data series using in forecasting. Note that when a statistical model is used to represent ImmunoCellular Therapeutics pink sheet, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.AIC | Akaike Information Criteria | 108.9406 |
Bias | Arithmetic mean of the errors | 0.0086 |
MAD | Mean absolute deviation | 0.0489 |
MAPE | Mean absolute percentage error | 0.0707 |
SAE | Sum of the absolute errors | 2.885 |
Predictive Modules for ImmunoCellular Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as ImmunoCellular Therapeutics. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of ImmunoCellular Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
ImmunoCellular Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ImmunoCellular Therapeutics pink sheet to make a market-neutral strategy. Peer analysis of ImmunoCellular Therapeutics could also be used in its relative valuation, which is a method of valuing ImmunoCellular Therapeutics by comparing valuation metrics with similar companies.
Risk & Return | Correlation |
ImmunoCellular Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how ImmunoCellular Therapeutics pink sheet reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading ImmunoCellular Therapeutics shares will generate the highest return on investment. By undertsting and applying ImmunoCellular Therapeutics pink sheet market strength indicators, traders can identify ImmunoCellular Therapeutics entry and exit signals to maximize returns.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in ImmunoCellular Pink Sheet
If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
CEOs Directory Screen CEOs from public companies around the world |